NBOMe series

NBOMe series refers to a group of synthetic psychedelic compounds derived from the phenethylamine class of psychoactive drugs. These compounds are known for their potent hallucinogenic effects and are structurally related to other well-known psychedelics such as 2C compounds. The NBOMe series has gained attention both for their use in psychotherapy and recreational settings, as well as for the associated risks and legal status.

Chemistry

The NBOMe compounds are characterized by the addition of a 2-methoxybenzyl (NBOMe) group to the amine nitrogen of the corresponding 2C compound. This modification significantly increases the potency of these compounds compared to their 2C counterparts. Common compounds in this series include 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe, each differing only in the substitution on the benzene ring of the phenethylamine core structure.

Pharmacology

The NBOMe series acts primarily as highly potent agonists for the 5-HT2A receptor, which is a subtype of the serotonin receptor found in the brain. Activation of this receptor is primarily responsible for the compounds' hallucinogenic effects. Due to their high potency, these compounds can be active at microgram-level doses, making them significantly more potent than other classical psychedelics.

Effects

The effects of NBOMe compounds can vary significantly but generally include intense visual and auditory hallucinations, altered perception of time and space, euphoria, and introspection. However, these effects come with a high risk of negative outcomes, including confusion, agitation, and in some cases, severe toxicity leading to medical emergencies.

Risks and Toxicity

The NBOMe series has been associated with numerous adverse events, including fatalities. These compounds have a narrow therapeutic index, making the margin between recreational dose and overdose very small. Adverse effects can include severe vasoconstriction, cardiac arrest, seizures, and acute psychosis.

Legal Status

Due to the health risks and potential for abuse, many countries have moved to control NBOMe compounds under their drug laws. For instance, in the United States, several NBOMe compounds have been temporarily scheduled under the Controlled Substances Act due to their similarity to LSD and their potential for abuse and lack of accepted medical use.

See Also

• Designer drug
• Drug policy
• Hallucinogen
• Psychedelic therapy